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cThe  study  by  Grandi  et  al.  provides  important  information
about  the  prevalence  and  impact  of  maternal  diabetes  mel-
litus  on  the  outcomes  of  very  low  birth  weight  infants  in
South  American  neonatal  intensive  care  units  (NICUs).  They
report  an  overall  rate  of  maternal  diabetes  of  2.8%,  with
an  increase  in  prevalence  from  2001-2005  of  2.4%  to  3.2%
over  the  period  between  2006-2010.  Also,  of  the  numerous
perinatal  and  neonatal  outcomes  examined  in  this  cohort
of  almost  12,000  infants,  only  severe  necrotizing  enterocol-
itis  was  associated  with  diabetes  mellitus  in  multivariable
regression.1 These  data  differ  from  other  published  results.
Prior  studies  of  the  prevalence  of  gestational  diabetes  range
from  an  estimated  2-6%  of  cases  across  European  countries,25-11%  within  15  states  of  the  US,3 and  16%  in  Qatar.4 Several
studies  from  both  low-  and  middle-income  countries5 and
developed  countries6 also  show  diabetes  as  a  risk  factor
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he  entire  population  versus  a  speciﬁc,  high-risk  popula-
ion  such  as  that  studied  by  Grandi  et  al.1 What  do  these
ndings,  or  any  similar  ﬁndings,  mean  for  the  clinicians  or
olicy  makers  overseeing  the  care  delivered  to  high-risk
ewborns,  especially  in  light  of  data  suggesting  that  rates  of
estational  diabetes  in  other  countries  is  increasing?7 Prac-
itioners  should  assess  the  validity  of  the  results  and  then
etermine  the  potential  impact  of  these  results  on  their
ractice.
For  any  study,  we  should  examine  whether  the  data  are
ccurate  before  any  actions  are  undertaken.  Inaccuracies
an  occur  in  three  major  areas:2 could  the  diagnosis  be  made
n  all  women;  was  the  diagnostic  test  appropriate;  and  were
he  data  collected  on  each  pregnancy  correct.  For  a  condi-
ion  such  as  gestational  diabetes,  women  must  both  receive
renatal  care,  and  have  the  test  to  conﬁrm  either  the  pres-
nce  or  absence  of  the  condition.  Depending  on  the  hospital,
ealth  system,  or  country’s  population  and  social  dynam-
cs,  access  to  prenatal  care  or  to  the  tools  needed  to  make
he  diagnosis  may  be  limited.  Additionally,  for  diabetes,  one
tandard  diagnostic  procedure  is  a  1-  or  3-hour  glucose  test,
dministered  typically  at  24-28  weeks  gestation.  It  is  not
lear  what  percentage  of  women  who  delivered  before  28
eeks  gestation  could  have  had  the  diagnosis.  These  two
er Editora Ltda. All rights reserved.
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ituations  could  have  lower  the  reported  rate  of  diabetes  in
his  or  any  other  similar  study.
Secondly,  it  is  important  that  the  correct  diagnostic
est  is  used.  Prior  studies  used  different  tests  to  diagnose
iabetes.2 This  study  group  speciﬁcally  suggested  the  World
ealth  Organization  oral  glucose  tolerance  test,  but  notes
hat,  with  data  collection  across  multiple  centers  in  mul-
iple  countries,  this  criterion  was  not  universally  followed.
owever,  the  fact  that  speciﬁc  tests  were  encouraged  at
ach  center  is  a  positive  aspect  of  the  data  collection.
inally,  larger  population-based  datasets  may  not  contain
he  correct  information  on  all  patients.  For  example,  mor-
ality  rates  may  differ  depending  on  the  data  source,8 likely
ecause  of  differences  in  the  accuracy  of  the  recorded  data,
epending  on  whether  registry  or  vital  statistics  data  are
sed.  The  use  of  a  detailed  registry  of  patients  such  as  that
f  the  Neocosur  Network,  with  built  in  methods  to  validate
he  recorded  data,  improves  the  reported  results.  All  of
hese  issues  may  result  in  inter-hospital  variations  in  health
utcomes  that  have  nothing  to  do  with  the  care  delivered,
ut  rather  differences  in  the  accuracy  of  the  data  or  differ-
nces  in  the  patients  included  in  the  measurement  in  the
rst  place.9 With  the  data  structures  in  place,  the  accuracy
f  these  data  are  likely  as  strong  as  they  can  be,  without
odifying  clinical  practices  at  each  individual  hospital  --
omething  that  is  challenging  to  do  across  multiple  hospital
ystems  in  multiple  countries.
After  assessing  the  validity  of  the  data,  such  reported
ariation  in  diabetes  mellitus  prevalence  and  impact  on  out-
ome  then  supports  the  idea  that  clinicians  should  know
he  patients  that  they  care  for,  especially  in  areas  that
iffer  from  those  areas  where  many  of  the  reported  stud-
es  occurred.  First,  the  lower  prevalence  of  diabetes  in
he  NICUs  of  these  22  hospitals  may  affect  decisions  about
dditional  screening  of  women  or  quality  improvement
nd  education  programs  to  address  either  the  diagnosis
r  treatment  of  diabetes  in  these  units.  Second,  the  fact
hat  diabetes  was  not  associated  with  adverse  outcomes  in
hese  patients  supports  other  work  showing  that  treatments
ay  have  different  effects  on  patient  health  depending
n  the  geographic  setting  they  are  delivered.  For  exam-
le,  numerous  studies  from  the  developed  world  show
he  beneﬁcial  effect  of  antenatal  corticosteroids  on  the
isease-free  survival  of  high-risk  infants.  A  recent  clus-
er  randomized  trial  of  corticosteroid  administration  in  six
ow-  and  middle-income  countries  (Argentina,  Guatemala,
ndia,  Kenya,  Pakistan,  and  Zambia),  though,  found  neona-
al  mortality  did  not  decrease  in  low  birth  weight  infants,
ith  increased  neonatal  mortality  and  maternal  infection
isk  overall  in  the  clusters  randomized  to  processes  of  care
esigned  to  increase  use  of  antenatal  corticosteroids.10 This
ifference  may  have  occurred  because  of  differences  in
he  baseline  maternal  health  in  these  six  countries  and  the
ifferent  health  resources  available  to  care  for  high-risk
hildren  in  these  countries  compared  to  the  pregnancies
ncluded  in  previous  studies  from  the  developed  world.11
owever,  there  can  also  be  variations  in  the  effect  of  a
peciﬁc  treatment  within  a  single  country.  The  impact  of
elivery  at  a  high-volume,  high-level  neonatal  intensive
are  unit  differed  across  three  states  in  the  US,  with  the
urvival  beneﬁt  ranging  from  30%  to  330%  depending  on  the
tate.  Similar  differences  were  seen  in  the  reduction  ofLorch  SA
ommon  complications  of  preterm  birth.12 The  three  states
iffered  in  the  distribution  of  racial/ethnic  backgrounds,
ealth  insurance  status,  and  prevalence  of  many  antepar-
um  complications  of  pregnancy.  Thus,  different  patient
opulations  may  have  different  medical  and  genetic  risks
f  disease.  However,  these  regions  also  differ  in  the  orga-
ization  of  perinatal  care,  with  different  processes  of  care
ith  regard  to  maternal  and  infant  transport  systems,  cen-
ralization  of  perinatal  services,  and  regionalization  of  care.
These  examples  illustrate  differences  the  casemix  of
ndividual  hospitals,  and  how  the  effect  of  common  treat-
ents  may  differ  depending  on  this  casemix.  It  is  likely,
hough,  that  the  patients  included  in  these  above  studies
nd  the  study  by  Grandi  et  al.  also  differed  in  social  factors
uch  as  housing,  education,  and  income.  While  not  as  fre-
uently  measured  in  perinatal  and  neonatal  studies,  these
‘social  determinants  of  health’’  may  inﬂuence  both  the
revalence  of  diseases  such  as  diabetes  and  also  the  ultimate
utcome  of  these  conditions.  Latin  America  is  not  immune
rom  these  adverse  social  determinants,13 and  in  fact  the
arallel  private/public  systems  that  are  common  in  many
atin  American  countries  may  differ  from  those  systems  that
are  for  patients  in  many  studies  of  neonatal  health  and
reatment.14 More  research  needs  to  focus  on  how  these
actors  affect  the  health  and  outcomes  of  these  high-risk
atients.
In  summary,  the  study  by  Grandi  et  al.  illustrates  the
mportance  of  understanding  the  patients  cared  for  by
ealth  care  groups,  whether  hospitals,  states,  or  countries,
nd  how  they  respond  to  speciﬁc  treatments.  Practition-
rs  discuss  personalized  medicine,  where  treatments  are
iven  depending  on  a  patient’s  genetic,  medical,  and
ocial  background.  We  should  think  about  how  different
atient  populations  have  different  risks  of  disease  that
equire  subtle  changes  to  management  plans  in  order  to
ptimize  patient  outcomes.  Understanding  of  these  best
ractices  is  needed  to  optimize  perinatal  and  neonatal
ealth.
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